| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10738311 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US10351854 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US11359203 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US11053502 | NOVO | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
Oct, 2035
(11 years from now) | |
| US11286488 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(14 years from now) | |
| US11661604 | NOVO | Methods and compositions for inhibiting expression of LDHA |
Oct, 2038
(14 years from now) | |
Rivfloza is owned by Novo.
Rivfloza contains Nedosiran Sodium.
Rivfloza has a total of 6 drug patents out of which 0 drug patents have expired.
Rivfloza was authorised for market use on 29 September, 2023.
Rivfloza is available in solution;injection dosage forms.
Rivfloza can be used as method of treating primary hyperoxaluria type 1 (ph1).
Drug patent challenges can be filed against Rivfloza from 30 September, 2027.
The generics of Rivfloza are possible to be released after 12 October, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-443) | Sep 29, 2030 |
| New Chemical Entity Exclusivity(NCE) | Sep 29, 2028 |
Drugs and Companies using NEDOSIRAN SODIUM ingredient
NCE-1 date: 30 September, 2027
Market Authorisation Date: 29 September, 2023
Treatment: Method of treating primary hyperoxaluria type 1 (ph1)
Dosage: SOLUTION;INJECTION
RIVFLOZA family patents
